Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 2
1978 1
1984 2
1985 7
1986 8
1987 7
1988 10
1989 10
1990 6
1991 6
1992 8
1993 9
1994 4
1995 5
1996 4
1997 11
1998 8
1999 9
2000 14
2001 9
2002 15
2003 19
2004 15
2005 9
2006 25
2007 21
2008 12
2009 17
2010 16
2011 13
2012 12
2013 17
2014 14
2015 14
2016 16
2017 17
2018 9
2019 11
2020 14
2021 10
2022 7
2023 8
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

424 results

Results by year

Filters applied: . Clear all
Page 1
Retinal vascular occlusions.
Scott IU, Campochiaro PA, Newman NJ, Biousse V. Scott IU, et al. Among authors: campochiaro pa. Lancet. 2020 Dec 12;396(10266):1927-1940. doi: 10.1016/S0140-6736(20)31559-2. Lancet. 2020. PMID: 33308475 Free PMC article. Review.
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants.
Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL, Burdon KP, Hebbring SJ, Wen C, Gorski M, Kim IK, Cho D, Zack D, Souied E, Scholl HP, Bala E, Lee KE, Hunter DJ, Sardell RJ, Mitchell P, Merriam JE, Cipriani V, Hoffman JD, Schick T, Lechanteur YT, Guymer RH, Johnson MP, Jiang Y, Stanton CM, Buitendijk GH, Zhan X, Kwong AM, Boleda A, Brooks M, Gieser L, Ratnapriya R, Branham KE, Foerster JR, Heckenlively JR, Othman MI, Vote BJ, Liang HH, Souzeau E, McAllister IL, Isaacs T, Hall J, Lake S, Mackey DA, Constable IJ, Craig JE, Kitchner TE, Yang Z, Su Z, Luo H, Chen D, Ouyang H, Flagg K, Lin D, Mao G, Ferreyra H, Stark K, von Strachwitz CN, Wolf A, Brandl C, Rudolph G, Olden M, Morrison MA, Morgan DJ, Schu M, Ahn J, Silvestri G, Tsironi EE, Park KH, Farrer LA, Orlin A, Brucker A, Li M, Curcio CA, Mohand-Saïd S, Sahel JA, Audo I, Benchaboune M, Cree AJ, Rennie CA, Goverdhan SV, Grunin M, Hagbi-Levi S, Campochiaro P, Katsanis N, Holz FG, Blond F, Blanché H, Deleuze JF, Igo RP Jr, Truitt B, Peachey NS, Meuer SM, Myers CE, Moore EL, Klein R, Hauser MA, Postel EA, Courtenay MD, Schwartz SG, Kovach JL, Scott WK, Liew G, Tan AG, Gopinath B, Merriam JC, Smith RT, K… See abstract for full author list ➔ Fritsche LG, et al. Among authors: campochiaro p. Nat Genet. 2016 Feb;48(2):134-43. doi: 10.1038/ng.3448. Epub 2015 Dec 21. Nat Genet. 2016. PMID: 26691988 Free PMC article.
Reply.
Campochiaro PA, Maass KF, Singh N, Barteselli G. Campochiaro PA, et al. Ophthalmology. 2019 Nov;126(11):e88-e89. doi: 10.1016/j.ophtha.2019.06.020. Ophthalmology. 2019. PMID: 31635711 No abstract available.
Reply.
Campochiaro PA, Mir TA, Han YS, Kherani S, Hafiz G, Krispel C, Liu TYA, Wang J, Scott AW, Zimmer-Galler I. Campochiaro PA, et al. Am J Ophthalmol. 2017 Nov;183:163-164. doi: 10.1016/j.ajo.2017.09.006. Epub 2017 Sep 20. Am J Ophthalmol. 2017. PMID: 28941645 No abstract available.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Reply.
Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, Sodhi A, Duh E, Ying HS, Wenick AS, Shah SM, Do DV, Nguyen QD, Kherani S, Sophie R. Campochiaro PA, et al. Ophthalmology. 2016 May;123(5):e33-4. doi: 10.1016/j.ophtha.2015.11.024. Ophthalmology. 2016. PMID: 27107360 No abstract available.
424 results